The true cost of treating invasive fungal infections in hospitals
We first created a generic framework to help decision-makers think about how to compare patient management whilst considering all costs to the healthcare provider. Then, we developed a specific tool for management of patients with invasive fungal disease (IFD). Lastly, we estimated that the attributable cost of managing adult haematology patients with IFD at Kings College Hospital (London) was more than £50,000 per case, with the inpatient stay cost far outstripping the cost of antifungal drugs.
The benefits and cost-savings of a new point-of-care test for chlamydia and gonorrhoea
We developed an understanding of how sexual health clinics in England could use a rapid point of care test for two common sexually transmitted infections. We defined the current patient care pathways and found that the pathways could be streamlined and costs of care reduced by using point-of-care tests. The economic model developed by Aquarius Population Health showed that the test could deliver £10 million in cost savings, and give far more effective management of chlamydia and gonorrhoea at a population level.
Benefits of a point of care test for sexual health testing
Managing Mycoplasma genitalium as an STI
The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study
Point-of-care testing leads the way: article in the Parliamentary Review 2014
Mapping patient pathways and cost of point of care versus standard testing and treatment for chlamydia and gonorrhoea in sexual health clinics
The cost of managing haematology patients with invasive fungal disease
The cost and tariff reimbursement of idiopathic pulmonary fibrosis in England
Treatment for stable HIV patients in England: can we save costs and improve patient care?